💊Executive Order on Most-Favored-Nation Drug Pricing Impact
Executive Order 14297 aims to rectify the disparity in pharmaceutical pricing between the U.S. and other developed countries. It emphasizes the need for Americans to access drugs at the most-favored-nation prices and outlines immediate policy actions to address foreign pricing disparities. The order also encourages direct-to-consumer sales at these pricing levels, asserting that U.S. patients should benefit from fair drug pricing relative to global standards.
Learn More📈HRSA Seeks Comments on Telehealth Performance Measurement ICR
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Learn More💰Nurse Corps Loan Repayment Program
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Learn More💊Medicare Drug Price Negotiation Program Draft Guidance Overview
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' draft guidance for the third cycle of the Medicare Drug Price Negotiation Program, the first cycle of renegotiation, and manufacturer effectuation of the maximum fair price for 2026, 2027, and 2028 for the implementation of the Inflation Reduction Act (IRA).
Learn More🏥Executive Order
The Executive Order aims to address homelessness among veterans by establishing the National Center for Warrior Independence in Los Angeles. It emphasizes restoring veteran care accountability, providing services, and ensuring housing assistance. The Order also outlines collaborative efforts with various agencies to enhance veterans' access to benefits and support services.
Learn More💊FDA Determines Regulatory Review Period for ADBRY Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More💰NIH Closed Meetings for Grant Applications Review
The Department of Health and Human Services announces closed meetings of the NIH's Center for Scientific Review to evaluate grant applications. These meetings cover various scientific panels focused on advancing health research and clinical practices. The discussions conducted during these meetings may involve confidential information, emphasizing the importance of compliance and discretion in grant processes.
Learn More🏥Business Implications of CMS Information Collection Notice
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More💊FDA Determines Regulatory Review Period for LITFULO Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LITFULO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More💰NIH Closure Notices for Grant Application Review Meetings
The Department of Health and Human Services announced closed meetings of the National Institutes of Health's Center for Scientific Review to evaluate grant applications. These meetings, which will occur virtually, will not be open to the public due to the confidential nature of the discussions, including sensitive patentable materials and personal data.
Learn More